WO2007047504A3 - Natriuretic peptide modified transferrin fusion proteins - Google Patents
Natriuretic peptide modified transferrin fusion proteins Download PDFInfo
- Publication number
- WO2007047504A3 WO2007047504A3 PCT/US2006/040207 US2006040207W WO2007047504A3 WO 2007047504 A3 WO2007047504 A3 WO 2007047504A3 US 2006040207 W US2006040207 W US 2006040207W WO 2007047504 A3 WO2007047504 A3 WO 2007047504A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion proteins
- natriuretic peptide
- peptide modified
- transferrin fusion
- modified transferrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Fusion proteins of transferrin and natriuretic peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002625600A CA2625600A1 (en) | 2005-10-14 | 2006-10-16 | Natriuretic peptide modified transferrin fusion proteins |
EP06825957A EP1951277A2 (en) | 2005-10-14 | 2006-10-16 | Natriuretic peptide modified transferrin fusion proteins |
JP2008535740A JP2009511060A (en) | 2005-10-14 | 2006-10-16 | Natriuretic peptide modified transferrin fusion protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72619805P | 2005-10-14 | 2005-10-14 | |
US60/726,198 | 2005-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007047504A2 WO2007047504A2 (en) | 2007-04-26 |
WO2007047504A3 true WO2007047504A3 (en) | 2007-06-14 |
Family
ID=37963135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/040207 WO2007047504A2 (en) | 2005-10-14 | 2006-10-16 | Natriuretic peptide modified transferrin fusion proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1951277A2 (en) |
JP (1) | JP2009511060A (en) |
CA (1) | CA2625600A1 (en) |
WO (1) | WO2007047504A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
CA2699916A1 (en) | 2007-09-18 | 2009-08-06 | The Jackson Laboratory | Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
US8551938B2 (en) | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
WO2011038061A2 (en) | 2009-09-25 | 2011-03-31 | Alcon Research, Ltd. | Novel npr-b agonists |
TW201121995A (en) | 2009-12-18 | 2011-07-01 | Alcon Res Ltd | Novel NPR-B agonists |
US9018168B2 (en) | 2010-08-12 | 2015-04-28 | Madeleine Pharmaceuticals Pty Ltd | Therapeutic method for treating congestive heart failure |
NZ724348A (en) | 2010-11-30 | 2019-12-20 | Genentech Inc | Low affinity blood brain barrier receptor antibodies and uses therefor |
EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
TW201442721A (en) * | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | Glycosilated atrial natriuretic peptide |
WO2014164981A1 (en) | 2013-03-12 | 2014-10-09 | The General Hospital Corporation | Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases |
ES2945994T3 (en) | 2013-03-15 | 2023-07-11 | Gladiator Biosciences Inc | Gla domains as addressing agents |
CA2933335A1 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation |
AU2015243961A1 (en) | 2014-04-10 | 2016-10-27 | Bayer Healthcare Llc | Compounded media powder formulation and method of preparation of liquid medium for cell culture |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403336B1 (en) * | 1985-06-20 | 2002-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Process for the production of α-human atrial natriuretic polypeptide |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US6987088B2 (en) * | 1999-07-02 | 2006-01-17 | Genentech, Inc. | Compounds that bind HER2 |
-
2006
- 2006-10-16 EP EP06825957A patent/EP1951277A2/en not_active Ceased
- 2006-10-16 JP JP2008535740A patent/JP2009511060A/en active Pending
- 2006-10-16 CA CA002625600A patent/CA2625600A1/en not_active Abandoned
- 2006-10-16 WO PCT/US2006/040207 patent/WO2007047504A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403336B1 (en) * | 1985-06-20 | 2002-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Process for the production of α-human atrial natriuretic polypeptide |
US6987088B2 (en) * | 1999-07-02 | 2006-01-17 | Genentech, Inc. | Compounds that bind HER2 |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
Non-Patent Citations (2)
Title |
---|
LI H. ET AL.: "Transferrin/Transferrin Receptor-Mediated Drug Delivery", MEDICINAL RESEARCH REVIEWS, vol. 22, no. 3, pages 225 - 250, XP003014317 * |
WANG W. ET AL.: "AlbuBNP, a Recombinant B-Type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure", PHARM. RES., vol. 21, no. 11, 2004, pages 2105 - 2110, XP003014318 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009511060A (en) | 2009-03-19 |
CA2625600A1 (en) | 2007-04-26 |
WO2007047504A2 (en) | 2007-04-26 |
EP1951277A2 (en) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007047504A3 (en) | Natriuretic peptide modified transferrin fusion proteins | |
WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
WO2004020405A3 (en) | Modified transferrin fusion proteins | |
IL160289A0 (en) | Modified transferrin fusion proteins | |
WO2004020454A3 (en) | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains | |
EP2949658A3 (en) | Peptides that specifically bind HGF receptor (cMet) and uses thereof | |
WO2006061219A3 (en) | Il-7 variants with reduced immunogenicity | |
WO2008079995A3 (en) | Conjugate of natriuretic peptide and antibody constant region | |
WO2006096515A3 (en) | Modified transferrin fusion proteins | |
WO2006113546A3 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
WO2006130834A3 (en) | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF | |
AU2003239365A8 (en) | Recombinant glycosyltransferase fusion proteins | |
WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
AU2002217010A1 (en) | Peptides, the production and use thereof for binding immunoglobulins | |
WO2005047459A3 (en) | Sars nucleic acids, proteins, antibodies, and uses thereof | |
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
WO2006049983A3 (en) | Peptide yy modified transferrin fusion proteins | |
WO2006076742A3 (en) | Methods and compositions for increasing membrane permeability | |
WO2004020588A3 (en) | Transferrin fusion protein libraries | |
WO2006127822A3 (en) | Scytovirin domain 1 related polypeptides | |
WO2008021412A3 (en) | Interferon beta and transferrin fusion proteins | |
WO2003020759A3 (en) | A caspase- 8 binding protein, its preparation and use | |
WO2007002510A3 (en) | A system and method to obtain oligo-peptides with specific high affinity to query proteins | |
WO2006123157A3 (en) | Nematistatic protein | |
WO2004033694A3 (en) | Promoter to il-18bp, its preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2625600 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2008535740 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006825957 Country of ref document: EP |